— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to $119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.
— FY2020 Screening revenue is expected to be $1.125-1.15 billion.
— FY2020 Precision Oncology revenue is expected to be $485-495 million.
— EXAS shares gained 1.2% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: How Lennar Corporation (LEN) performed in Q3 2024
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the third quarter of 2024, which was up 8% from the same period last year. Net earnings attributable to
FDX Earnings: FedEx Q1 2025 revenue and profit miss analysts’ estimates
Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decrease in revenues and adjusted earnings for the first quarter of 2025. The results also fell short of expectations. First-quarter earnings,
Signet (SIG) remains optimistic about its fiscal year 2025 performance, here’s why
Shares of Signet Jewelers Limited (NYSE: SIG) were up over 4% on Thursday. The stock has gained 24% over the past one month. The jewelry retailer saw revenue and profits
